|Podcasts|February 18, 2021

Episode 76: Repatriating Pharma

Joel Marcus, founder and executive chairman of Alexandria Real Estate Equities, and founder and CEO of Alexandria Venture Investments, talks about the effects of COVID on worldwide biomanufacturing, and what the repatriation of pharma could look like.

Joel Marcus, founder and executive chairman of Alexandria Real Estate Equities, and founder and CEO of Alexandria Venture Investments, discusses the drive to bring pharma manufacturing back to a company’s home country and the issues involved in doing so.

You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.


Related to this article

Pharmaceutical Executive Daily
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.
Pharmaceutical Executive Daily
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.